Ganoderic acid DM: Anti-androgenic osteoclastogenesis inhibitor

Jie Liu, Jun Shiono, Kuniyoshi Shimizu, Akiko Kukita, Toshio Kukita, Ryuichiro Kondo

Research output: Contribution to journalArticlepeer-review

53 Citations (Scopus)


Prostate cancer is the most common cancer in men in Western countries, with a high incidence of bone metastasis. Ganoderic acid DM, with 5α-reductase inhibitory and androgen receptor (AR) binding activity, isolated from the ethanol extracts of Ganoderma lucidum, can inhibit prostate cancer cell growth and block osteoclastogenesis.

Original languageEnglish
Pages (from-to)2154-2157
Number of pages4
JournalBioorganic and Medicinal Chemistry Letters
Issue number8
Publication statusPublished - Apr 15 2009

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Molecular Medicine
  • Molecular Biology
  • Pharmaceutical Science
  • Drug Discovery
  • Clinical Biochemistry
  • Organic Chemistry


Dive into the research topics of 'Ganoderic acid DM: Anti-androgenic osteoclastogenesis inhibitor'. Together they form a unique fingerprint.

Cite this